马约诊所经林业发展局批准,对阿尔茨海默氏氏症进行新的血液测试,可以非常准确地进行早期检测。 Mayo Clinic's new FDA-approved blood test for Alzheimer's offers early detection with high accuracy.

由马约诊所开发的阿尔茨海默氏病新的血液测试,能够以95%的敏感性和82%的特性检测早期症状。 A new blood test for Alzheimer's disease, developed by the Mayo Clinic, can detect early symptoms with 95% sensitivity and 82% specificity. 测试检查了血浆中的两种蛋白质,并已得到美国食品和药物管理局的批准。 The test examines two proteins in blood plasma and has been approved by the US Food and Drug Administration. 与目前的方法相比,这种血液测试可以提供更快、容易和更容易获得的诊断。 This blood test could provide a faster, easier, and more accessible diagnosis compared to current methods. 血液生物标志挑战旨在到2029年将类似的血液测试提交国民保健制度。 The Blood Biomarker Challenge aims to bring similar blood tests to the NHS by 2029.